Pieris Pharmaceuticals Inc. (NASDAQ: PIRS)
$7.51
+0.1000 ( +1.35% ) 43.9K
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
Market Data
Open
$7.51
Previous close
$7.41
Volume
43.9K
Market cap
$9.93M
Day range
$7.38 - $7.91
52 week range
$6.20 - $41.78
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 60 | Aug 10, 2023 |
8-k | 8K-related | 15 | Jul 18, 2023 |
8-k | 8K-related | 13 | Jul 13, 2023 |